Pfizer's FCPA settlement to top $60M; Valeant buys iNova for up to $698M;

 @FiercePharma: Regeneron prices wet AMD drug Eyela at $1850 per shot, $16K per yearr, compared with Roche's Lucentis at $24K annually. | Follow@FiercePharma

> Pfizer's settlement of U.S. foreign bribery probes will amount to more than $60 million, Wall Street Journal sources said, as a pharma-wide investigation of potential Foreign Corrupt Practices Act violations continues. Report

> Acquisition-hungry Valeant Pharmaceuticals has snapped up Australia's iNova Pharmaceuticals for up to $698 million, gaining a "beachhead" in Southeast Asia and South Africa. Report

> Members of the British parliament are investigating ongoing shortages of certain drugs, after allegations arose that the shortages have been caused by parallel trade. Report

> The European Patent Office granted a patent on the composition of GW Pharmaceuticals' recently approved drug Sativex. Report

> India's Dr Reddy's Laboratories said contract workers at its Andhra Pradesh manufacturing facility called off their strike and operations are back to normal. Report

> Foster children are being prescribed powerful antipsychotic drugs as frequently as some of the most mentally disabled kids, a new study finds. Report

> Omnicare said it has given the Federal Trade Commission information about its buyout offer for rival PharMerica. Report

Biotech News

 @FierceBiotech: With 20% of vote, Sanofi's Viehbacher is leading our poll on the most influential CEOs in pharma. Vote | Follow @FierceBiotech

 @JohnCFierce: If these Pharmasset drugs work as Gilead hopes, qualifies for '14 OK, then Gilead is a hero. If they don't, Gilead is a goat. Hero or goat. | Follow @JohnCFierce

 @RyanMFierce: Unfortunately for $REGN, it can undercut Lucentis price and still face uphill battle competing with off-label Avastin in wet AMD. | Follow @RyanMFierce

 @MaureenFierce: Celldex brain cancer vaccine increases survival in Phase II. Report | Follow @MaureenFierce

 @MarkHFierce: ImClone/Lilly's Erbitux and Roche's Tarceva as brain tumor treatment? Expanded indications would equal greater value. Story | Follow @MarkHFierce

Medical Device News

 

> Covidien to buy BARRX for $325M. News

> FDA to investigate stent shrinkage. Article

> BeneChill names former Boston Sci exec as new CEO. Item

> Survey: Irish medtech companies looking to hire next year. Piece

 

Biotech IT News

 

> Tufts to tackle tough issue of lengthy trial startups. Story

> Perceptive Informatics survey focuses on role of imaging in clinical trials. Report

> Biotech billionaire mounts digital attack on cancer. Report

> Scripps begins world's largest computer-based project against malaria. News

> Biotech heavyweight Art Levinson takes chairman job at Apple.  Article

And Finally... Debate over birth-control coverage rules has cropped up again, as President Obama weighs a broader exemption for institutions affiliated with religious groups. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.